Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-schedule temozolomide for recurrent low-grade oligodendroglial tumors (Phase II)
2007-000386-38Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- May 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in Oligodendroglioma (OG) and oligoastrocytoma, sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Response to chemotherapy by MacDonald and Hoang-Xuan criteria. Started May 2007; status: active.
02
Drugs
temozolomide
03
Conditions
Oligodendroglioma (OG)oligoastrocytoma
Beyond the preview
Go deeper on 2007-000386-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000386-38.